尿激酶升高与α2-抗纤溶酶消耗可解释延迟使用氨甲环酸后获益丧失
该研究在血浆和全血凝块溶解体系中探讨氨甲环酸(TXA)延迟使用后失效的机制。结果显示TXA可保护纤维蛋白,但会协同尿激酶型纤溶酶原激活物(uPA)生成活性纤溶酶并消耗α2-抗纤溶酶,导致凝血病;抑肽酶直接抑制纤溶酶可能延长TXA的有效时间窗。
要点
- TXA与uPA在血浆或全血中生成活性纤溶酶并引发凝血病,与tPA无关。
- 凝血病程度取决于可用α2-抗纤溶酶,其消耗加重纤溶酶诱导的凝血病。
- 抑肽酶直接抑制纤溶酶(血浆IC50=530 nmol L-1)可能防止凝血病。
核心结论
- TXA保护纤维蛋白但刺激uPA活性并减慢α2-抗纤溶酶对纤溶酶的抑制,纤溶酶蛋白水解活性消化纤维蛋白原并破坏凝血,当α2-抗纤溶酶被持续纤溶消耗时加重。
- 抑肽酶对纤溶酶的额外直接抑制可能防止凝血病发生并延长TXA治疗的有效时间窗。
研究设计与样本
- 在多种血浆和全血凝块溶解体系中探讨TXA的抑制机制,研究组织型纤溶酶原激活物(tPA)、uPA和纤溶酶诱导的溶解。
- 使用ROTEM和活化部分凝血活酶时间(APTT)评估凝血病。
主要发现
- TXA抗纤溶活性的IC50值因体系不同从<10至>1000 μmol L-1不等,但在tPA、uPA和纤溶酶存在时均观察到良好的纤维蛋白保护。
- 在血浆或全血中,TXA+uPA(而非tPA)生成活性纤溶酶并发生凝血病,导致无或不良凝块形成。
- 含40%正常α2-抗纤溶酶的血浆经TXA+uPA短时间孵育后无凝块形成,加入纯化α2-抗纤溶酶可逐步恢复凝血。
- 在血浆中,抑肽酶可抑制纤溶酶,IC50=530 nmol L-1。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials Delayed treatment with tranexamic acid results in loss of efficacy and poor outcomes. Increasing urokinase activity may account for adverse effects of late tranexamic acid treatment. Urokinase + tranexamic acid produces plasmin in plasma or blood and disrupts clotting. α2 -Antiplasmin consumption with ongoing fibrinolysis increases plasmin-induced coagulopathy. SUMMARY: Background Tranexamic acid (TXA) is an effective antifibrinolytic agent with a proven safety record. However, large clinical trials show TXA becomes ineffective or harmful if treatment is delayed beyond 3 h. The mechanism is unknown but urokinase plasminogen activator (uPA) has been implicated. Methods Inhibitory mechanisms of TXA were explored in a variety of clot lysis systems using plasma and whole blood. Lysis by tissue plasminogen activator (tPA), uPA and plasmin were investigated. Coagulopathy was investigated using ROTEM and activated partial thromboplastin time (APTT). Results IC50 values for antifibrinolytic activity of TXA varied from < 10 to > 1000 μmol L-1 depending on the system, but good fibrin protection was observed in the presence of tPA, uPA and plasmin. However, in plasma or blood, active plasmin was generated by TXA + uPA (but not tPA) and coagulopathy developed leading to no or poor clot formation. The extent of coagulopathy was sensitive to available α2 -antiplasmin. No clot formed with plasma containing 40% normal α2 -antiplasmin after short incubation with TXA + uPA. Adding purified α2 -antiplasmin progressively restored clotting. Plasmin could be inhibited by aprotinin, IC50 = 530 nmol L-1 , in plasma. Conclusions Tranexamic acid protects fibrin but stimulates uPA activity and slows inhibition of plasmin by α2 -antiplasmin. Plasmin proteolytic activity digests fibrinogen and disrupts coagulation, exacerbated when α2 -antiplasmin is consumed by ongoing fibrinolysis. Additional direct inhibition of plasmin by aprotinin may prevent development of coagulopathy and extend the useful time window of TXA treatment.
引用
- Longstaff C, Locke M. Increased urokinase and consumption of α2 -antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay. J Thromb Haemost. 2018. PMID: 30451372. doi:10.1111/jth.14338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。